# A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.

> **NCT06307457** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 604 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Palbociclib in combination with AI

## Key facts

- **NCT ID:** NCT06307457
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-06
- **Primary completion:** 2024-04-19
- **Final completion:** 2024-04-19
- **Target enrollment:** 604 (ACTUAL)
- **Last updated:** 2025-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06307457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06307457, "A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06307457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*